Veldoreotide

Drug Profile

Veldoreotide

Alternative Names: COR-005; DG-3173; PTR-3173; Veldotide

Latest Information Update: 26 Nov 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Peptor
  • Class Antineoplastics; Cyclic peptides; Eye disorder therapies
  • Mechanism of Action Somatostatin receptor 2 agonists; Somatostatin receptor 5 agonists; Somatostatin receptor subtype 4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acromegaly
  • Phase I Adrenal cortical hyperfunction; Diabetic retinopathy; Neuroendocrine tumours

Most Recent Events

  • 18 Nov 2015 Somatoprim receives Orphan Drug status for Acromegaly in European Union
  • 04 Sep 2015 Cortendo is now called Strongbridge Biopharma
  • 20 Jul 2015 Somatoprim is still in phase II trials for Acromegaly (Treatment-naive) in the Ukraine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top